Illumina (NASDAQ:ILMN) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Illumina (NASDAQ:ILMN) in a report released on Sunday. The brokerage set a “buy” rating on the life sciences company’s stock.

A number of other analysts also recently commented on ILMN. Barclays increased their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. TD Cowen decreased their price target on Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research report on Thursday, June 6th. Jefferies Financial Group assumed coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. Robert W. Baird raised their target price on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Scotiabank decreased their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research report on Monday, May 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $157.62.

Illumina Stock Performance

Shares of Illumina stock opened at $105.50 on Friday. The company has a market cap of $16.81 billion, a PE ratio of -12.94 and a beta of 1.20. Illumina has a 52 week low of $89.00 and a 52 week high of $195.64. The business has a 50 day moving average price of $111.62 and a 200-day moving average price of $127.32. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. Illumina’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the business posted $0.08 earnings per share. Equities analysts anticipate that Illumina will post 0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

A number of large investors have recently made changes to their positions in the stock. Bouvel Investment Partners LLC boosted its stake in Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after buying an additional 84 shares during the period. STF Management LP boosted its stake in Illumina by 3.5% during the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after buying an additional 90 shares during the period. Global Retirement Partners LLC boosted its stake in Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after buying an additional 94 shares during the period. Gulf International Bank UK Ltd boosted its stake in Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after buying an additional 98 shares during the period. Finally, Clear Creek Financial Management LLC boosted its stake in Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after buying an additional 100 shares during the period. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.